391
Participants
Start Date
June 30, 2022
Primary Completion Date
August 15, 2024
Study Completion Date
September 11, 2024
CVL-231 15 mg
CVL-231 15 mg, oral (tablet), once per day for 6 weeks
Required CVL-231 30 mg
CVL-231 30 mg, oral (tablet), once per day for 6 weeks
Placebo
Matching placebo, oral (tablet), once per day for 6 weeks
Budapest, Budapest, Budapest
Sofia, Sofia, Sofia
Sofia, Sofia-Grad, Sofia
Pleven, Pleven, Pleven
Kalocsa, Bács-Kiskun, Kalocsa
Burgas, Burgas, Burgas
Győr, Győr-Moson-Sopron, Győr
Chicago, Illinois, Chicago
Bentonville, Arkansas, Bentonville
Bellflower, California, Bellflower
La Habra, California, La Habra
San Diego, California, San Diego
Sherman Oaks, California, Sherman Oaks
Torrance, California, Torrance
New Haven, Connecticut, New Haven
Homestead, Florida, Homestead
Miami, Florida, Miami
Miami Lakes, Florida, Miami Lakes
Miami Springs, Florida, Miami Springs
Atlanta, Georgia, Atlanta
Savannah, Georgia, Savannah
Chicago, Illinois, Chicago
Berlin, New Jersey, Berlin
Marlton, New Jersey, Marlton
Charlotte, North Carolina, Charlotte
Austin, Texas, Austin
Lead Sponsor
AbbVie
INDUSTRY